{
    "organizations": [],
    "uuid": "07e152ac8c1062f4fa439290380a8309b70e79c3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-arix-bioscience-and-ipsen-signs-st/brief-arix-bioscience-and-ipsen-signs-strategic-agreement-to-develop-and-commercialise-innovative-therapies-idUSFWN1QB08D",
    "ord_in_thread": 0,
    "title": "BRIEF-Arix Bioscience And Ipsen Signs Strategic Agreement To Develop And Commercialise Innovative Therapies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 21 (Reuters) - Arix Bioscience Plc:\n* ARIX BIOSCIENCE AND IPSEN SIGN A STRATEGIC AGREEMENT TO DEVELOP AND COMMERCIALISE INNOVATIVE THERAPIES\n* IPSEN WILL CONTRIBUTE RESEARCH, DEVELOPMENT AND COMMERCIAL EXPERTISE TO PARTNERSHIP\n* ARIX WILL PROVIDE IPSEN WITH ACCESS TO ITS UNIQUE NETWORK OF PROFESSIONAL AND SCIENTIFIC ADVISORS Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\n ",
    "published": "2018-02-21T15:25:00.000+02:00",
    "crawled": "2018-02-22T17:44:48.015+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "arix",
        "bioscience",
        "plc",
        "arix",
        "bioscience",
        "ipsen",
        "sign",
        "strategic",
        "agreement",
        "develop",
        "commercialise",
        "innovative",
        "therapy",
        "ipsen",
        "contribute",
        "research",
        "development",
        "commercial",
        "expertise",
        "partnership",
        "arix",
        "provide",
        "ipsen",
        "access",
        "unique",
        "network",
        "professional",
        "scientific",
        "advisor",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}